Sean Duffy Sells 2,800 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 2,800 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $19.01, for a total value of $53,228.00. Following the sale, the chief executive officer directly owned 409,061 shares of the company’s stock, valued at approximately $7,776,249.61. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Omada Health Stock Performance

Shares of OMDA opened at $20.89 on Friday. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92. The firm’s 50 day moving average price is $16.51 and its two-hundred day moving average price is $14.85. The firm has a market cap of $1.24 billion and a P/E ratio of -77.37.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.03. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. The company had revenue of $78.05 million during the quarter. On average, sell-side analysts anticipate that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a report on Friday, May 8th. BMO Capital Markets reduced their price objective on Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Evercore reissued an “outperform” rating and issued a $20.00 target price on shares of Omada Health in a research report on Friday, May 8th. Citizens Jmp boosted their target price on Omada Health from $18.00 to $21.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 price target on shares of Omada Health in a research report on Monday, June 22nd. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.91.

Institutional Investors Weigh In On Omada Health

Large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new position in Omada Health during the second quarter worth $32,000. Quarry LP acquired a new stake in Omada Health in the fourth quarter valued at $29,000. TD Waterhouse Canada Inc. bought a new position in shares of Omada Health in the 4th quarter valued at about $32,000. Inlight Wealth Management LLC bought a new position in shares of Omada Health in the 4th quarter valued at about $45,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Omada Health during the 3rd quarter worth about $82,000.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.